BlackRock takes 5% stake in S Korean biotech firm during FDA review
BlackRock has acquired a 5.01% stake in HLB, a South Korean biotech firm developing a liver cancer drug candidate, Rivoceranib.
HLB’s regulatory filing said BlackRock Fund Advisors bought 6,664,921 shares on the open market as of Feb. 24 for a simple investment purpose.
……Read full article on Tech in Asia
Other
One-stop lifestyle app dedicated to making life in Singapore a breeze!
English
简体中文
Comments
Leave a comment in Nestia App